Major depressive disorder

Major depressive disorder
source
Name	Major depressive disorder
Field	Psychiatry

Major depressive disorder is a common psychiatric condition characterized by persistent low mood and loss of interest that impair functioning. It presents across diverse settings from primary care clinics to specialized centers and affects individuals across ages, socioeconomic groups, and cultures. Management typically involves combinations of psychotherapy, pharmacotherapy, and somatic treatments guided by clinical guidelines and specialist judgment.

Overview

Major depressive disorder occurs in contexts ranging from episodic courses seen in outpatient clinics to chronic presentations managed in inpatient units and long-term care facilities. Presentation can overlap with bipolar spectrum conditions evaluated by clinicians at institutions such as Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and specialty research centers including National Institute of Mental Health and university departments like Harvard Medical School and University of Oxford. Epidemiologic studies from agencies like the World Health Organization and surveys conducted by organizations such as the Centers for Disease Control and Prevention inform burden estimates and guide policy at ministries of health in nations like United States, United Kingdom, India, and China.

Signs and symptoms

Core symptoms include depressed mood, anhedonia, change in appetite or weight, sleep disturbance, psychomotor changes, fatigue, diminished concentration, feelings of worthlessness or guilt, and recurrent thoughts of death or suicide. Symptom clusters are described in diagnostic manuals used by clinicians at institutions like the American Psychiatric Association, influenced by research from investigators at centers such as Stanford University, Columbia University, and University of California, Los Angeles. Severe cases may require admission to facilities like Cleveland Clinic or transfer to specialty units that coordinate with emergency departments at hospitals such as Mount Sinai Hospital.

Causes and risk factors

Etiology is multifactorial, involving genetic vulnerability identified in cohorts assembled by consortia such as the Psychiatric Genomics Consortium, neurobiological alterations studied at laboratories in institutes like Max Planck Institute for Psychiatry, and life events documented in longitudinal studies conducted by universities like Yale University and University of Cambridge. Environmental risks include adverse childhood experiences recorded in longitudinal cohorts from institutions such as University College London and disaster-related stressors examined by teams at Columbia University Mailman School of Public Health. Medical comorbidity with conditions treated at centers like Cleveland Clinic and Johns Hopkins Hospital—including endocrine disorders and neurological diseases—modulates risk. Socioeconomic gradients reported by agencies such as the Organisation for Economic Co-operation and Development and population studies in countries like Brazil and South Africa show variation in incidence and prevalence.

Diagnosis and screening

Diagnosis uses criteria from manuals published by bodies such as the American Psychiatric Association and assessment instruments validated in multicenter studies at institutions like King's College London and University of Toronto. Screening programs in primary care settings often utilize brief scales endorsed by organizations including the United States Preventive Services Task Force and implementation research from groups at Imperial College London. Differential diagnosis involves ruling out bipolar disorder, substance-induced mood disorder, and medical mimics evaluated by specialists at centers such as Mayo Clinic and Massachusetts General Hospital, often aided by structured interviews used in research at institutions like Columbia University.

Treatment

First-line treatments include evidence-based psychotherapies delivered by clinicians trained at institutes like Beck Institute and pharmacotherapies developed by pharmaceutical researchers at companies that collaborate with universities such as University of Oxford and University of Cambridge. Antidepressant classes demonstrated in randomized controlled trials overseen by regulatory agencies including the Food and Drug Administration and European Medicines Agency are commonly prescribed. For treatment-resistant cases, options include electroconvulsive therapy provided in hospital programs at centers like Sheppard Pratt Health System and neuromodulation techniques developed in research centers such as National Institute of Mental Health and implemented at tertiary centers like Johns Hopkins Hospital. Collaborative care models tested in trials at institutions like University of Washington and RAND Corporation integrate primary care and mental health specialists. Psychosocial interventions often engage community resources including advocacy groups like National Alliance on Mental Illness and support services coordinated with public health departments in cities such as New York City and Los Angeles.

Prognosis and epidemiology

Prognosis varies: many individuals experience relapse and recurrence documented in cohort studies from centers such as Duke University and University of Michigan, while others achieve sustained remission with treatment strategies evaluated in long-term trials at institutions such as Vanderbilt University Medical Center. Global prevalence estimates come from analyses by the World Health Organization and large surveys performed by organizations like the Global Burden of Disease Study managed by teams at Institute for Health Metrics and Evaluation. Epidemiologic patterns show demographic differences reported by national surveys from agencies such as the Centers for Disease Control and Prevention and public health ministries in countries including Australia and Germany. Risk of suicide, highlighted in reports from agencies like the Suicide Prevention Resource Center and national statistics offices, underscores the need for timely identification and management in healthcare systems across jurisdictions like Canada and Sweden.

Category:Mental disorders